A COVID-19 vaccine platform that enables rapid production of second-generation vaccines against SARS-CoV-2 variants of concern has been developed by University of Melbourne researchers.
Partner with us to support funding of GMP manufacture and stage 1 clinical trials for the second-generation COVID-19 vaccine.
The innovation
A vaccine platform targeting the SARS-CoV-2 receptor binding domain for generating COVID-19 vaccines that can rapidly incorporate emerging variants. The UoM vaccine technology offers potential production and manufacturing advantages including the delivery of abundant, temperature-stable vaccine doses at an affordable cost.
Market need
Several SARS-CoV-2 variants of concern have emerged that efficiently escape the neutralising antibody response raised by first-generation vaccines or previous infection. Second-generation COVID-19 vaccine candidates are needed to manage the pandemic.
Innovation status
Researchers have designed appropriate scaffolds for the receptor binding domain to enhance and focus the most effective immunity response against COVID-19. Further preclinical evaluation is currently underway.
Contact
Dr Anna Malinovitch
anna.malinovitch@unimelb.edu.au
Flyer
Download flyer for more information (PDF, 540 KB)
Keep reading
-
Negotiating a licence with the University
By licensing the University of Melbourne’s intellectual property (IP) and technologies, you can harness research discoveries to solve business challenges.
-
Our IP principles
Our Intellectual Property (IP) management principles make it easier to collaborate with us.
-
Investing in University startups
Find out about new ways to invest in University startups
-
Contact
From developing an idea to finding startup funding, the University of Melbourne’s team of experts can help.